Altimmune (ALT) Change in Account Payables (2010 - 2026)
Altimmune (ALT) reported Change in Account Payables of -$1.2 million for Q1 2026, down 237.07% year-over-year from $866000.0 in Q1 2025, and up 43.12% quarter-over-quarter from -$2.1 million in Q4 2025.
Altimmune (ALT) Change in Account Payables (2010 - 2026) Analysis & Trends
Altimmune (ALT) has 17 years of Change in Account Payables data on file, last reported at -$1.2 million in Q1 2026.
- Change in Account Payables for Q1 2026 came in at -$1.2 million, down 237.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $453000.0 (up 116.88% YoY), and the FY2025 annual result was $2.5 million, up 234.8% from the prior year.
- Change in Account Payables climbed to -$1.2 million in Q1 2026 per ALT's latest filing, from -$2.1 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $4.0 million in Q3 2025 and troughed at -$2.1 million in Q4 2025.
- A 5-year average of -$29647.1 and a median of -$922000.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2023 and 2025: Change in Account Payables sank 280.36% in 2023, then soared 354.21% in 2025.
- A 5-year view of Change in Account Payables shows it stood at $3.4 million in 2022, then sank by 128.83% to -$976000.0 in 2023, then grew by 5.53% to -$922000.0 in 2024, then tumbled by 126.36% to -$2.1 million in 2025, then jumped by 43.12% to -$1.2 million in 2026.
- Business Quant data shows ALT's Change in Account Payables at -$1.2 million in Q1 2026, -$2.1 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -9.42 Mn |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | -1.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.19 Mn |
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | -2.09 Mn |
| Dec 31, 2025 | -2.09 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Sep 30, 2025 | 3.95 Mn |
| Jun 30, 2025 | -226,000.00 |
| Jun 30, 2025 | -226,000.00 |
| Mar 31, 2025 | 866,000.00 |
| Mar 31, 2025 | 866,000.00 |
| Dec 31, 2024 | -922,000.00 |
| Dec 31, 2024 | -922,000.00 |
| Sep 30, 2024 | -1.56 Mn |
| Sep 30, 2024 | -1.56 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Jun 30, 2024 | -1.07 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Mar 31, 2024 | 1.69 Mn |
| Dec 31, 2023 | -976,000.00 |
| Dec 31, 2023 | -976,000.00 |